POWERED BY BIOHM Trademark

Trademark Overview


On Thursday, September 2, 2021, a trademark application was filed for POWERED BY BIOHM with the United States Patent and Trademark Office. The USPTO has given the POWERED BY BIOHM trademark a serial number of 97008640. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Tuesday, April 9, 2024. This trademark is owned by Biohm Health LLC. The POWERED BY BIOHM trademark is filed in the Pharmaceutical Products category with the following description:

Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liqu...
powered by biohm

General Information


Serial Number97008640
Word MarkPOWERED BY BIOHM
Filing DateThursday, September 2, 2021
Status732 - THIRD EXTENSION - GRANTED
Status DateTuesday, April 9, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 16, 2022

Trademark Statements


Goods and ServicesProbiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; nutritional supplements, namely, probiotic compositions in the nature of a vaginal probiotic for the treatment and prevention of bacterial and fungal vaginal infection; nutraceuticals for the treatment and prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's Disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's Disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's Disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibers in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's Disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; microbial and biological preparations for medical use, namely, probiotics, for improving the physical well-being of humans, namely, reducing inflammation and pain; dietary supplements for medical use and baby food containing microorganisms, namely, metabolites obtained from the processing of probiotic bacterial cultures; probiotic and nutritional and dietary supplements; antifungal preparations; antifungal creams for medical use; vaginal antifungal preparations; fungal extracts sold as a component ingredient of nutritional supplments and vitamins and bacterial probiotic supplements, and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's Disease, ulcerative colitis and irritable bowel syndrome; beverages containing probiotic compositions for use as a nutritional supplement; food supplements containing probiotic compositions; human food supplements containing probiotic compositions; animal food products containing probiotic compositions, namely, probiotic animal feed; dietary supplement drink mixes, namely, probiotic compositions in the form of mixes to added to beverages; dietary supplements in the nature of probiotic compositions for mixing with cereal; medical specimens collection kits for the collection of body fluids comprised of swabs for medical purposes, a sealable collection container and sample bag; medical specimens collection kits for the collection of body fluids comprised of swabs for medical purposes, a sealable collection container, sample bag, mailer envelope, ID sticker, and swab applicator; diagnostic biological testing kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic genetic testing kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic microbiota testing kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; medical specimen collection kits for the collection of body fluids comprised of medical specimen bags and cups

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, July 13, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBIOHM HEALTH INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressCLEVELAND, OH 44113

Party NameBiohm Health LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressCleveland, OH 44115

Party NameBiohm Health LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressCleveland, OH 44115

Trademark Events


Event DateEvent Description
Wednesday, April 10, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 9, 2024SOU EXTENSION 3 GRANTED
Tuesday, April 9, 2024SOU EXTENSION 3 FILED
Tuesday, April 9, 2024SOU TEAS EXTENSION RECEIVED
Friday, October 13, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 11, 2023SOU EXTENSION 2 GRANTED
Wednesday, October 11, 2023SOU EXTENSION 2 FILED
Wednesday, October 11, 2023SOU TEAS EXTENSION RECEIVED
Friday, April 21, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 20, 2023SOU EXTENSION 1 GRANTED
Friday, April 7, 2023SOU EXTENSION 1 FILED
Wednesday, April 19, 2023AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Friday, April 14, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, April 7, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, October 11, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 16, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 16, 2022PUBLISHED FOR OPPOSITION
Wednesday, July 27, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, July 14, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 13, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, July 12, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 12, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, January 12, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, January 12, 2022NON-FINAL ACTION E-MAILED
Wednesday, January 12, 2022NON-FINAL ACTION WRITTEN
Monday, January 10, 2022ASSIGNED TO EXAMINER
Friday, October 15, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED